Logo image of TBPH

THERAVANCE BIOPHARMA INC (TBPH) Stock Fundamental Analysis

NASDAQ:TBPH - Nasdaq - KYG8807B1068 - Common Stock - Currency: USD

9.45  +0.06 (+0.64%)

After market: 9.45 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TBPH. TBPH was compared to 198 industry peers in the Pharmaceuticals industry. TBPH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, TBPH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TBPH had negative earnings in the past year.
In the past year TBPH had a positive cash flow from operations.
TBPH had negative earnings in 4 of the past 5 years.
In the past 5 years TBPH always reported negative operating cash flow.
TBPH Yearly Net Income VS EBIT VS OCF VS FCFTBPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

1.2 Ratios

The Return On Assets of TBPH (-16.98%) is better than 64.65% of its industry peers.
TBPH has a Return On Equity of -35.14%. This is in the better half of the industry: TBPH outperforms 60.10% of its industry peers.
Industry RankSector Rank
ROA -16.98%
ROE -35.14%
ROIC N/A
ROA(3y)37.73%
ROA(5y)0.15%
ROE(3y)46.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TBPH Yearly ROA, ROE, ROICTBPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TBPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TBPH Yearly Profit, Operating, Gross MarginsTBPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

More info and screens

6

2. Health

2.1 Basic Checks

TBPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TBPH has more shares outstanding
Compared to 5 years ago, TBPH has less shares outstanding
Compared to 1 year ago, TBPH has a worse debt to assets ratio.
TBPH Yearly Shares OutstandingTBPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
TBPH Yearly Total Debt VS Total AssetsTBPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -2.23, we must say that TBPH is in the distress zone and has some risk of bankruptcy.
TBPH's Altman-Z score of -2.23 is in line compared to the rest of the industry. TBPH outperforms 47.98% of its industry peers.
The Debt to FCF ratio of TBPH is 0.96, which is an excellent value as it means it would take TBPH, only 0.96 years of fcf income to pay off all of its debts.
TBPH has a Debt to FCF ratio of 0.96. This is amongst the best in the industry. TBPH outperforms 94.95% of its industry peers.
TBPH has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of TBPH (0.19) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 0.96
Altman-Z -2.23
ROIC/WACCN/A
WACC9.76%
TBPH Yearly LT Debt VS Equity VS FCFTBPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 4.77 indicates that TBPH has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.77, TBPH is in the better half of the industry, outperforming 72.22% of the companies in the same industry.
TBPH has a Quick Ratio of 4.77. This indicates that TBPH is financially healthy and has no problem in meeting its short term obligations.
TBPH has a better Quick ratio (4.77) than 73.23% of its industry peers.
Industry RankSector Rank
Current Ratio 4.77
Quick Ratio 4.77
TBPH Yearly Current Assets VS Current LiabilitesTBPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for TBPH have decreased strongly by -30.23% in the last year.
Looking at the last year, TBPH shows a small growth in Revenue. The Revenue has grown by 6.18% in the last year.
Measured over the past years, TBPH shows a decrease in Revenue. The Revenue has been decreasing by -2.59% on average per year.
EPS 1Y (TTM)-30.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
Revenue 1Y (TTM)6.18%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.59%
Sales Q2Q%6.1%

3.2 Future

Based on estimates for the next years, TBPH will show a very strong growth in Earnings Per Share. The EPS will grow by 36.06% on average per year.
TBPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.04% yearly.
EPS Next Y68.74%
EPS Next 2Y2.72%
EPS Next 3Y18.85%
EPS Next 5Y36.06%
Revenue Next Year52.05%
Revenue Next 2Y12.91%
Revenue Next 3Y19.57%
Revenue Next 5Y31.04%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TBPH Yearly Revenue VS EstimatesTBPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
TBPH Yearly EPS VS EstimatesTBPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TBPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TBPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TBPH Price Earnings VS Forward Price EarningsTBPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, TBPH is valued cheaply inside the industry as 87.37% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 14.64
EV/EBITDA N/A
TBPH Per share dataTBPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as TBPH's earnings are expected to grow with 18.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.72%
EPS Next 3Y18.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TBPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERAVANCE BIOPHARMA INC

NASDAQ:TBPH (5/20/2025, 8:00:01 PM)

After market: 9.45 0 (0%)

9.45

+0.06 (+0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-04 2025-08-04
Inst Owners94.28%
Inst Owner Change0.58%
Ins Owners5.82%
Ins Owner Change1.94%
Market Cap472.50M
Analysts80
Price Target15.56 (64.66%)
Short Float %8.17%
Short Ratio15.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.41%
Min EPS beat(2)-44.72%
Max EPS beat(2)-16.1%
EPS beat(4)0
Avg EPS beat(4)-26.03%
Min EPS beat(4)-44.72%
Max EPS beat(4)-10.35%
EPS beat(8)2
Avg EPS beat(8)-14.88%
EPS beat(12)3
Avg EPS beat(12)-28.11%
EPS beat(16)5
Avg EPS beat(16)-26.92%
Revenue beat(2)1
Avg Revenue beat(2)2.46%
Min Revenue beat(2)-2.67%
Max Revenue beat(2)7.58%
Revenue beat(4)2
Avg Revenue beat(4)0.79%
Min Revenue beat(4)-9.55%
Max Revenue beat(4)7.78%
Revenue beat(8)4
Avg Revenue beat(8)-0.96%
Revenue beat(12)5
Avg Revenue beat(12)-4.23%
Revenue beat(16)6
Avg Revenue beat(16)-5.07%
PT rev (1m)5.17%
PT rev (3m)10.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20%
EPS NY rev (1m)0%
EPS NY rev (3m)-414.35%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-0.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.24
P/FCF 14.64
P/OCF 14.53
P/B 2.85
P/tB 2.85
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)0.65
FCFY6.83%
OCF(TTM)0.65
OCFY6.88%
SpS1.31
BVpS3.32
TBVpS3.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.98%
ROE -35.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 49.47%
ROA(3y)37.73%
ROA(5y)0.15%
ROE(3y)46.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 0.96
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.77
Quick Ratio 4.77
Altman-Z -2.23
F-Score4
WACC9.76%
ROIC/WACCN/A
Cap/Depr(3y)20.39%
Cap/Depr(5y)43.25%
Cap/Sales(3y)1.99%
Cap/Sales(5y)4.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
EPS Next Y68.74%
EPS Next 2Y2.72%
EPS Next 3Y18.85%
EPS Next 5Y36.06%
Revenue 1Y (TTM)6.18%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.59%
Sales Q2Q%6.1%
Revenue Next Year52.05%
Revenue Next 2Y12.91%
Revenue Next 3Y19.57%
Revenue Next 5Y31.04%
EBIT growth 1Y-10.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y118.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y118.9%
OCF growth 3YN/A
OCF growth 5YN/A